Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13298630 | 1.00 | PSD (0.44) | PSDKIF11KCNQ3KCNQ2GPR3 | |
| SCHEMBL13298643 | 0.91 | HDAC8 (0.40) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298635 | 0.91 | HDAC8 (0.40) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298640 | 0.91 | HDAC8 (0.40) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298634 | 0.90 | ESR1 (0.45) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL22993304 | 0.88 | KIF11 (0.44) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298636 | 0.87 | ESR1 (0.43) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298645 | 0.87 | ESR1 (0.43) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL13298639 | 0.87 | ESR1 (0.43) | PSDKIF11KCNQ3KCNQ2CYP1A1 | |
| SCHEMBL22993301 | 0.86 | CYP1A1 (0.47) | PSDKIF11CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100133996-A1 | Novel anthracene typed compound and the organic electroluminescence display device using the same | DONGJIN SEMICHEM CO., LTD (KR) | 2010-06-03 | — | — | US | disclosed |
| US-20100133996-A1 | Novel anthracene typed compound and the organic electroluminescence display device using the same | DONGJIN SEMICHEM CO., LTD (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100133996-A1 | Novel anthracene typed compound and the organic electroluminescence display device using the same | TRPA1, TRPM2, TRPM4 | PSD 2490/4885KIF11 2827/4885KCNQ3 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.